## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

Claims 1-20 (Cancelled).

- Claim 21. (Currently Amended): A method for determining vascular endothelial growth factor (VEGF) activity in a sample, said method comprising the steps of:
  - a) contacting a sample to be assayed for VEGF activity with a stable HeLa cell line wherein the stable HeLa cell line comprises;
    - 1) a reporter vector having; an expressible reporter element and a DNA binding site disposed adjacent thereto and,
    - 2) a chimeric transactivator vector comprising
      a gene encoding a phosphorylatable protein that can be phosphorylated by
      MAPK and a DNA binding domain which specifically binds to the DNA binding site, and
    - 3) an expression vector encoding a gene for a VEGF receptor; and
  - b) detecting expression of the reporter element, wherein expression of the reporter element indicates VEGF activity [A method according to Claim 1,] wherein the sample comprises cells, tissue, tissue extracts or combinations thereof.

Claims 22-24 (Cancelled).

Ò

- Claim 25. (Currently Amended) A method for determining vascular endothelial growth factor (VEGF) activity in a sample, said method comprising the steps of:
  - a) Contacting a sample to be assayed for VEGF activity with a stable HeLa cell line wherein the stable HeLa cell line comprises;
    - 1) a reporter vector having; an expressible reporter element and a DNA binding site disposed adjacent thereto and,
    - 2) a chimeric transactivator vector comprising

a gene encoding a phosphorylatable protein that can be phosphorylated by

MAPK and a DNA binding domain which specifically binds to the DNA

binding site, and

3) an expression vector encoding a gene for a VEGF receptor; and
b) detecting expression of the reporter element, wherein expression of the reporter
element indicates VEGF activity [A method according to Claim 1,] further comprising the
step of incubating the sample with the stable Hela cell line for a period of time ranging
from approximately 10 hours to approximately 20 hours.

Claims 26-50 (Cancelled)